GlassScriptPhysician profile
Michael K Rushing
NPI 1386373082
$21,498.48
in general payments reported to CMS, 2019-2025
12 companies · $8,098 in 2025
The $8,098 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $4,825 · 2024: $8,575 · 2025: $8,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $5,687 · Food and Beverage: $3,551 · Consulting Fee: $80.00 · Honoraria: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,130.00 |
| Travel and Lodging | $5,687.05 |
| Food and Beverage | $3,551.43 |
| Consulting Fee | $80.00 |
| Honoraria | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $20,121.14 | 2023-2025 | Arrow |
| Astrazeneca Pharmaceuticals LP | $388.98 | 2023-2024 | Andexxa, Airsupra, Lokelma |
| Lilly USA, LLC | $179.59 | 2023-2025 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $139.57 | 2025 | |
| Novo Nordisk INC | $137.57 | 2024 | Rybelsus, Ozempic |
| Abbvie INC. | $130.25 | 2023 | |
| Edwards Lifesciences Corporation | $122.95 | 2025 | |
| Sanofi-Aventis U.S. LLC | $106.13 | 2024 | |
| Scpharmaceuticals INC. | $106.00 | 2024 | |
| Neurelis, INC. | $28.28 | 2024 | Valtoco |
| Btg International INC. | $21.70 | 2023 | |
| Gebauer Company | $16.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.